

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

REQUEST FOR ACCESS OF ABANDONED APPLICATION UNDER 37 CFR 1.14(a)

RECEIVED

MAY 14 2001

File Information Unit

In re Application of

Application Number

Filed

Group Art Unit

Examiner

Paper No.

Assistant Commissioner for Patents
Washington, DC 20231

I hereby request access under 37 CFR 1.14(a)(3)(iv) to the application file record of the above-identified ABANDONED application, which is: (CHECK ONE)

___ (A) referred to in United States Patent Number 6180370, column _____,

___ (B) referred to in an application that is open to public inspection as set forth in 37 CFR 1.11, i.e., Application No. _____, filed _____, on page _____ of paper number _____,

___ (C) an application that claims the benefit of the filing date of an application that is open to public inspection, i.e., Application No. _____, filed _____, or

___ (D) an application in which the applicant has filed an authorization to lay open the complete application to the public.

Please direct any correspondence concerning this request to the following address:

Stanley Perry
Signature
Stanley Perry
Typed or printed name

5/14/01
Date

FOR PTO USE ONLY

Approved by: _____
(initials)

Unit: _____

Burden Hour Statement: This form is estimated to take 0.2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

OTHER PUBLICATIONS

- Better et al., "Escherichia coli Secretion of an Active Chimeric Antibody Fragment," *Science*, 240:1041-1043 (1988).
- Bird et al., "Single-Chain Antigen-Binding Proteins," *Science*, 242:423-426 (1988).
- Boulianne et al., "Production of functional chimeric mouse/human antibody," *Nature*, 312:643-646 (1984).
- Carter et al., "Humanization of an anti-p185^{HER2} antibody for human cancer therapy," *Proc. Natl. Acad. Sci.*, 89:4285-4289 (1992).
- Chothia, C. and A.M. Lesk, "Canonical Structures for the Hypervariable Regions of Immunoglobulins," *J. Mol. Biol.*, 196:901-917 (1987).
- Co et al., "Humanized antibodies for antiviral therapy," *Proc. Natl. Acad. Sci.*, 88:2869-2873 (1991).
- Co et al., "Chimeric and humanized antibodies with specificity for the CD33 antigen," *J. Immunol.*, 148:1149-1154 (1992).
- Daugherty et al., "Polymerase chain reaction facilitates the cloning, CDR-grafting, and rapid expansion of a murine monoclonal antibody directed against the CD18 component of leukocyte integrins," *Nuc. Acids. Res.*, 19:2471-2476 (1991).
- Ellison et al., "The nucleotide sequence of a human immunoglobulin c(gamma)₁ gene," *Nucleic Acids Res.*, 10:4071- (1982).
- Farrar, J., "The biochemistry, biology, and the role of interleukin-2 in the induction of cytotoxic T cell and antibody-forming B cell receptors," *Immunol. Rev.*, 63:129-166 (1982).
- Foot et al., "Antibody framework residues affecting the conformation of hypervariable loops," *J. Mol. Biol.*, 224:487-499 (1992).
- Gorman et al., "Reshaping a therapeutic CD4 antibody," *Proc. Natl. Acad. Sci.*, 88:4181-4185 (1991).
- Greene et al., "Growth of Human T Lymphocytes: An Analysis of Interleukin 2 and its Cellular receptor," *Progress in Hematology XIV*, E. Brown, ed., Grune and Statton, New York, pp. 283-301 (1986).
- Hale et al., "Remission Induction in Non-Hodgkin Lymphoma with Reshaped Human Monoclonal Antibody CAMPATH-1H," *Lancet*, Dec. 17, 1988, pp. 1394-1399.
- Heiter et al., "Cloned Human and Mouse Kappa Immunoglobulin Constant and J. Region Genes Conserve Homology in Functional Segments," *Cell*, 22:197-207 (1980).
- Huston et al., "Protein engineering of antibody binding sites: Recovery of specific activity in an anti-digoxin single-chain Fv analogue produced in Escherichia coli," *Proc. Natl. Acad. Sci. USA*, 85:5879-5883 (1988), *Progress in Hematology XIV*, E. Brown, ed., Grune and Statton, New York, p. 283, (1986).
- Jones et al., "Replacing the complementarity-determining regions in a human antibody with those from a mouse," *Nature*, 321:522-525 (1986).
- Junghans et al., *Cancer Res.*, 50:1495-1502 (1990).
- Kettleborough et al., "Humanization of a mouse monoclonal antibody by CDR-grafting: the importance of framework residues on loop conformation," *Protein Eng.*, 4:773-783 (1991).
- Kirkman et al., *J. Exp. Med.*, 162:358 (1985).
- Kupiec-Weglinski et al., *Proc. Natl. Acad. Sci.*, 3:2624 (1986).
- Leonard et al., "The human receptor for T-cell growth factor," *J. Biol. Chem.*, 260:1872-1880 (1985).
- Liu et al., "Expression of mouse::human immunoglobulin heavy-chain cDNA in lymphoid cells," *Gene*, 54:33-40 (1987).
- Maeda et al., "Construction of reshaped human antibodies with HIV-neutralizing activity," *Hum. Antibod. Hybrid.*, 2:124-134 (1991).
- Morrison et al., "Chimeric human antibody molecules: Mouse antigen binding-domains with human constant region domains," *Proc. Natl. Acad. Sci.*, 81:6851-6859 (1984).
- Morrison, S.L., "Transfectomas Provide Novel Chimeric Antibodies," *Science*, 229:1202-1207 (1985).
- Neuberger et al., "A hapten-specific chimeric IgE antibody with human physiological effector function," *Nature*, 314:268-270 (1985).
- Queen et al., "A humanized antibody that binds to the interleukin 2 receptor," *Proc. Natl. Acad. Sci.*, 86:10029-10033 (1989).
- Riechmann et al., "Reshaping human antibodies for therapy," *Nature*, 332:323-327 (1988).
- Routledge et al., "A humanized monovalent CD3 antibody which can activate homologous complement," *Eur. J. Immunol.*, 21:2717-2725 (1991).
- Sahagan et al., "A Genetically Engineered Murine/Human Chimeric Antibody Retains Specificity for Human Tumor-Associated Antigen," *J. Immunol.*, 137:1066-1074 (1986).
- Shalaby et al., "Development of humanized bispecific antibodies reactive with cytotoxic lymphocytes and tumor cells overexpressing the HER2 protooncogene," *J. Exp. Med.*, 175:217-225 (1992).
- Sharon et al., "Expression of a V_HC_K chimaeric protein in mouse myeloma cells," *Nature*, 309:364-367 (1984).
- Shearman et al., "Construction, expression and characterization of humanized antibodies directed against the human α/β T cell receptor," *J. Immunol.*, 147:4366-4373 (1991).
- Takeda et al., "Construction of chimaeric processed immunoglobulin genes containing mouse variable and human constant region sequences," *Nature*, 314:452-454 (1985).
- Tan et al., "A Human-Mouse Chimeric Immunoglobulin Gene with a Human Variable Region is Expressed in Mouse Myeloma Cells," *J. Immunol.*, 135:3564-3567 (1985).
- Tempest et al., "Reshaping a human monoclonal antibody to inhibit human respiratory syncytial virus infection in vivo," *Bio/Technology*, 9:26-271 (1991).
- Uchiyama et al., "A monoclonal antibody (anti-Tac) reactive with activated and functionally mature human T-cells," *J. Immunol.*, 126:1393-1397 (1981).
- Verhoyen et al., "Reshaping Human Antibodies: Grafting an Antilysozyme Activity," *Science*, 239:1534-1536 (1988).
- Vitteta et al., "Redesigning nature's Poisons to Create Anti-Tumor Reagents," *Science*, 238:1098-1104 (1987).
- Waldmann, T.A., "The Structure, Function, and Expression of Interleukin-2 Receptors on Normal and Malignant Lymphocytes," *Science*, 232:727-732 (1986).
- Woodle et al., "Humanized OKT3 antibodies: successful transfer of immune modulating properties and idiotype expression," *J. Immunol.*, 148:2756-2763 (1992).
- Amit et al., *Science*, 233, 747-753 (1986).
- Cheetham, Protein Engineering, 2(3), 170-172 (1988).
- Chothia et al., *J. Mol. Biol.*, 186, 651-663 (1985).
- Chothia et al., *Nature*, 342, 877-883 (1989).

- Chothia et al., *Science*, 233, 755-758 (1986).
Chothia and Lesk, *EMBO J.*, 5, 823-826 (1986).
Colman et al., *Nature*, 326, 358-362 (1987).
Davies et al., *Ann. Rev. Immunol.*, 1, 87-117 (1983).
Davies et al., *J. Biol. Chem.*, 263(22), 10541-10544 (1988).
Epp et al., *Eur. J. Biochem.*, 45, 513-524 (1974).
Feldmann et al., *Mol. Immunol.*, 18, 683-698 (1981).
Kabat, *J. Immunol.*, 125, 961-969 (1980).
Lesk and Chothia, *J. Mol. Biol.*, 160, 325-342 (1982).
Padlan, *Mol. Immunol.*, 31, 169-217 (1994).
Palm et al., *Hoppe Seyler's Z. Physiol. Chem.*, 354(12), 1651-1654 (1973). Abstract.
Palm et al., *Hoppe Seyler's Z. Physiol. Chem.*, 356, 167-191 (1975). Abstract only.
Panka et al., *PNAS—USA*, 85, 3080-3084 (1988).
Roberts et al., *Nature*, 328, 731-734 (1987).
Saul et al., *J. Biol. Chem.*, 253(2), 585-597 (1978).
Sheriff et al., *PNAS—USA*, 84, 8075-8079 (1987).
Stanford and Wu, *J. Theor. Biol.*, 88, 421-439 (1981).
Tramontano et al., *J. Mol. Biol.*, 215, 175-182 (1990).
Verhoeven et al., *BioEssays*, 8(2), 74-78 (1988).
Waldmann et al., *Cancer Research*, 45, 4559s-4562s (1985).
Wu and Kabat, *J. Exp. Med.*, 132, 211-250 (1970).
Opposition to EP 0456216, Third Party Observations, May 25, 1998.
Opposition to EP 0456216, Further Submissions of Medical Research Council, Jun. 24, 1998.
Opposition to EP 0456216, Summons to Attend Oral Proceedings, May 12, 1999.
Opposition to EP 0456216, Further Submissions of Protein Design Labs, Inc., Sep. 17, 1999.
Opposition to EP 0456216, Further Submissions of Protein Design Labs, Inc., Oct. 26, 1999.
Opposition to EP 0456216, Further Submissions of Protein Design Labs, Inc., Dec. 1, 1999.
Opposition to EP 0456216, Further Third Party Observations, Dec. 14, 1999.
Opposition to EP 0456216, Further Submissions of Celltech Therapeutics, Dec. 16, 1999.
Opposition to EP 0456216, Attachment to Celltech Therapeutics' submissions of Dec. 16, 1999: Declaration of Thornton/Martin.
Opposition to EP 0456216, Attachment to Celltech Therapeutics' submissions of Dec. 16, 1999: printouts from Protein Design Labs, Inc.'s website.
Opposition to EP 0456216, Attachment to Celltech Therapeutics' submissions of Dec. 16, 1999: Tables showing derivatization of the antibody domains referred to in Fig. 3 / line 4 and Fig. 4F of WO 88/09344.
Opposition to EP 0456216, Attachment to Celltech Therapeutics' submissions of Dec. 16, 1999: Schomburg, in *Advances in Protein Design*, Blöcker et al. (Eds.), 1989, pp. 45-56.
Opposition to EP 0456216, Further Submissions of Genentech, Inc., Dec. 17, 1999.
Opposition to EP 0456216, Attachment to Genentech's submissions of Dec. 17, 1999: Declaration of Verhoeven (including exhibits A, B and C).
Opposition to EP 0456216, Attachment to Genentech's submissions of Dec. 17, 1999: Declaration of Shak (including exhibits A, B and C).
Opposition to EP 0456216, Attachment to Genentech's submissions of Dec. 17, 1999: Declaration of Presta (including exhibits A and B).
Opposition to EP 0456216, Attachment to Genentech's submissions of Dec. 17, 1999: Reply of Protein Design Labs, Inc. in European patent application 92903551.7.
Opposition to EP 0456216, Attachment to Genentech's submissions of Dec. 17, 1999: Letter of Dr. Seemann.
Opposition to EP 0456216, Observations of Protein Design Labs, Inc., Dec. 17, 1999.
Opposition to EP 0456216, Attachment to Observations of Protein Design Labs, Inc. submitted on Dec. 17, 1999: Declaration of F. Vincenti (including exhibits 1 and 2).
Opposition to EP 0456216, Attachment to Observations of Protein Design Labs, Inc. submitted on Dec. 17, 1999: Declaration of D. A. Scheinberg (including exhibits 1-4).
Opposition to EP 0456216, Attachment to Observations of Protein Design Labs, Inc. submitted on Dec. 17, 1999: Declaration of M. Sung Co and Experimental report.
Opposition to EP 0456216, Attachment to Observations of Protein Design Labs, Inc. submitted on Dec. 17, 1999: Declaration of C. Nan Chang and Experimental report.
Opposition to EP 0456216, Attachment to Observations of Protein Design Labs, Inc. submitted on Dec. 17, 1999: Declaration of R.D. Kornberg.
Opposition to EP 0456216, Attachment to Observations of Protein Design Labs, Inc. submitted on Dec. 17, 1999: Declaration of M. Levitt.
Opposition to EP 0456216, Attachment to Observations of Protein Design Labs, Inc. submitted on Dec. 17, 1999: Declaration of A. B. Edmundson.
Opposition to EP 0456216, Attachment to Observations of Protein Design Labs, Inc. submitted on Dec. 17, 1999: Declaration of R. Kirkman.
Opposition to EP 0456216, Attachment to Observations of Protein Design Labs, Inc. submitted on Dec. 17, 1999: Declaration of R. Junghans (including exhibits 1-6).
Opposition to EP 0456216, Attachment to Observations of Protein Design Labs, Inc. submitted on Dec. 17, 1999: Declaration of M. Vasquez.
Opposition to EP 0456216, Attachment to Observations of Protein Design Labs, Inc. submitted on Dec. 17, 1999: Declaration of D. Panka.
Opposition to EP 0456216, Attachment to Observations of Protein Design Labs, Inc. submitted on Dec. 17, 1999: Declaration of R. J. Poljak.
Opposition to EP 0456216, Attachment to Observations of Protein Design Labs, Inc. submitted on Dec. 17, 1999: Declaration of J. S. Huston.
Opposition to EP 0456216, Attachment to Observations of Protein Design Labs, Inc. submitted on Dec. 17, 1999: Declaration of C. Queen and experimental report.
Opposition to EP 0456216, Attachment to Observations of Protein Design Labs, Inc. submitted on Dec. 17, 1999: Declaration of N. Tsurushita and experimental report.
Opposition to EP 0456216, Attachment to Observations of Protein Design Labs, Inc. submitted on Dec. 17, 1999: Declaration of W. Smith.
Opposition to EP 0456216, Attachment to Observations of Protein Design Labs, Inc. submitted on Dec. 17, 1999: Examiner's Reasons for Allowance for U.S. Patent No. 5,225,539.
Opposition to EP 0456216, Further Submissions of Schering Corp., Feb. 11, 2000.
Opposition to EP 0456216, Further Submissions of Genentech, Inc., Mar. 8, 2000.

- Opposition to EP 0456216, Attachment to Genentech's submissions of Mar. 8, 2000: Declaration of Foote.
- Opposition to EP 0456216, Further Submissions of Genentech, Inc., Mar. 13, 2000.
- Opposition to EP 0456216, Further Submissions of Protein Design Labs, Inc., Mar. 16, 2000.
- Opposition to EP 0456216, Minutes of Oral Proceedings issued by the EPO, Apr. 5, 2000.
- Wu and Kabat, *J. Exp. Med.*, 132 (1970) 211-250.
- Palm, Hoppe-Seyler's *Z. Physio. Chem.* 354 (1973), 1651-1654 Abstract only.
- Epp., *Eur. J. Biochem.* 45 (1974), 513-524.
- Palm, Hoppe-Seyler's *Z. Physio. Chem.* 356 (1975), 167-191 Abstract only.
- Padlan, Cold Spring Harbor Symposia on Quantitative Biology, XLI (41) (1977), 627-637.
- Saul, *J. Biol. Chem.*, 253 (1978), 585-597.
- Kabat, *J. Immunol.*, 125 (1980), 961, 969.
- Lesk and Chothia, *J. Mol. Biol.*, 136 (1980), 225-270.
- Stanford, *J. theor. Biol.*, 88 (1981), 421-439.
- Feldman, *Mol. Immunol.*, 18 (1981), 683-698.
- Uchiyama, *J. Immunol.*, 126 (1981), 1393-1397.
- Lesk and Chothia, *J. Mol. Biol.*, 160 (1982), 325-342.
- Davies and Metzger, *Ann. Rev. Immunol.*, 1 (1983), 87-117.
- Chothia and Lesk, *Nature*, 302 (1983), 500-505.
- Kabat, Sequences of Proteins of Immunological Interest, US Dept. of Health and Human Services, 1983 Edition.
- Boulianne, *Nature*, 312 (1984), 643-646.
- Morrison, *Proc. Natl. Acad. Sci., USA*, 81 (1984) 6851-6855.
- Neuberger, *Nature*, 314 (1985), 651-663.
- Chothia, *J. Mol. Biol.*, 186 (1985), 651-663.
- Waldmann, *Science*, 232 (1986), 727-732.
- Waldmann, *Cancer Res.*, 45 (1985) 4559-4562.
- Amit, *Science*, 233 (1986), 747-753.
- Chothia, *Science*, 233 (1986), 755-758.
- Chothia and Lesk, *EMBO J.* 5 (1986), 823-826.
- Jones, *Nature*, 321 (1986), 522-525.
- Kabat, Sequences of Proteins of Immunological Interest, US Dept. of Health and Human Services, 1987 Edition pp. vi-xxvii.
- Chothia and Lesk, *J. Mol. Biol.*, 196 (1987), 901-917.
- Sheriff, *Proc. Natl. Acad. Sci., USA* 84 (1987), 8075-8079.
- Roberts, *Nature*, 328 (1987), 731-734.
- Verhoeyen, *BioEssays* 8 (Feb./Mar. 1988), 74-78.
- Riechmann, *Nature* 332 (Mar. 1988), 323-327.
- Verhoeyen, *Science* 239 (Mar. 1988), 1534-1536.
- Panka, *Proc. Natl. Acad. Sci. USA* 85 (May 1988) 3080-3084.
- Davies, *J. Biol. Chem.*, 263 (1988), 10541-10544.
- Cheetham, *Prot. Eng.*, 2 (Sep. 1988) 170-172.
- Matsumura, *Nature*, 334 (1988), 406-410.
- Hale, *The Lancet* 2 (Dec. 17, 1988), 1394-1399.
- Queen, *Proc. Natl. Acad. Sci., USA* 86 (Dec. 1989), 10029-10033.
- Chothia, *Nature*, 342, (1989), 877-883.
- Tramontano, *J. Mol. Biol.*, 215 (1990), 175-182.
- Co, *Proc. Natl. Acad. Sci., USA* 88 (1991), 2869-2873.
- Gorman, *Proc. Natl. Acad. Sci., USA*, 88 (1991), 4181-4185.
- Routledge, *Eur. J. Immunol.*, 21 (1991), 2717-2725.
- Shearman, *J. Immunol.*, 147 (1991), 4366-4373.
- Kettleborough, *Protein Engineering*, 4, (1991), 773-783.
- Tempest, *Bio/Technology*, 9, (1991), 266-271.
- Kabat, Sequences of Proteins of Immunological Interest, US Dept. of Health and Human Services, 1991 Edition pp. vii-xxvii.
- Co, *J. Immunol.*, 148, (1992), 1149-1154.
- Foote, *J. Mol. Biol.*, 224, (1992), 487-499.
- Carter, *Proc. Natl. Acad. Sci., USA*, 89 (1992) 4285-4289.
- Tempest, *Hybridoma*, 13 (1994), 183-190.
- Corti, *J. Mol. Biol.*, 235 (1994), 53-60.
- Adair, *Hum. Antibod. Hybridomas*, 5, (1994), 41-47.
- Padlan, *Molecular Immunol.*, 31 (1994), 169-217.
- Ellis, *J. Immunol.*, 155 (1995), 925-937.
- Tempest, *Int. J. Biol. Macromol.*, 17 (1995), 37-42.
- Ohtomo, *Molecular Immunology*, 32 (1995), 407-416.
- Co, *Cancer Res.*, 56 (1996), 1118-1125.
- Rosen, *Dictionary of Immunology*, 12, 50, 99, 100.
- Rodrigues, *Int. J. Cancer: Supplement* 7 (1992) 45-50.
- Sha, *Cancer Biotherapy*, 9 (1994), 341-349.
- Couto, *Hybridoma*, 13 (1994), 215-219.
- Couto, *Cancer Research, Supplement* 55, (1995), 1717-1722.
- Nakatani, *Protein Engineering*, 7, (1994), 435-443).
- Presta, *Cancer Research*, 57, (1997), 4593-4599.
- Hieter, *J. Biol. Chem.*, 257, (1982), 1516-1522.
- "Polygen Corporation" in New Products, Chemical Design Corporation, Automation, 3(11), Nov. 1988.
- "Biosym Technologies" in New Products, Chemical Design Automation, 3(4), Dec. 1988.
- Vicenti, *New Engl. J. Med.*, 338 (1998), 161-165.